WO1996036350B1 - Utilisation d'il-13 pour induire la 15-lipoxygenase - Google Patents
Utilisation d'il-13 pour induire la 15-lipoxygenaseInfo
- Publication number
- WO1996036350B1 WO1996036350B1 PCT/US1996/006779 US9606779W WO9636350B1 WO 1996036350 B1 WO1996036350 B1 WO 1996036350B1 US 9606779 W US9606779 W US 9606779W WO 9636350 B1 WO9636350 B1 WO 9636350B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- activity
- lta
- human
- hydroxylase
- inflammatory condition
- Prior art date
Links
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 title 1
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 14
- 230000000694 effects Effects 0.000 claims abstract 11
- 230000004968 inflammatory condition Effects 0.000 claims abstract 8
- 230000001939 inductive effect Effects 0.000 claims abstract 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract 3
- 230000004054 inflammatory process Effects 0.000 claims abstract 3
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 210000001616 monocyte Anatomy 0.000 claims abstract 2
- UFPQIRYSPUYQHK-WAQVJNLQSA-N leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 6
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 6
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 6
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 claims 6
- 101710156627 Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 230000000754 repressing effect Effects 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 229930184725 Lipoxin Natural products 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002639 lipoxins Chemical class 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- IXAQOQZEOGMIQS-SSQFXEBMSA-N lipoxin A4 Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-SSQFXEBMSA-N 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Abstract
La présente invention se fonde sur la découverte que l'IL-13 favorise la production de 15-LO chez les monocytes humains. Contrairement à ce qu'on pourrait attendre, l'IL-13 s'avère environ dix fois plus active, sur une base molaire, que l'IL-4 dans la production de 15-LO. L'IL-13 est donc une substance thérapeutique efficace dans le cas d'états inflammatoires réagissant aux produits de l'activité du 15-LO, notamment 15-S-HETE et LXA4. En favorisant des voies endogènes conduisant à la synthèse de molécules anti-inflammatoires endogènes, l'administration d'IL-13 aboutit à l'inhibition des effecteurs terminaux du processus inflammatoire lui-même. La stratégie employée consiste donc à intervenir directement sur des molécules pathogènes spécifiques, par opposition à la méthode actuelle qui consiste à traiter les symptômes de l'inflammation.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU60224/96A AU6022496A (en) | 1995-05-19 | 1996-05-13 | Use of il-13 to induce 15-lipoxygenase |
| JP8534942A JPH11505247A (ja) | 1995-05-19 | 1996-05-13 | １５−リポキシゲナーゼを誘導するためのｉｌ−１３の使用 |
| EP96917810A EP0831889A4 (fr) | 1995-05-19 | 1996-05-13 | Utilisation d'il-13 pour induire la 15-lipoxygenase |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/445,311 | 1995-05-19 | ||
| US08/445,311 US5830453A (en) | 1995-05-19 | 1995-05-19 | Use of IL-13 to induce 15-lipoxygenase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996036350A1 WO1996036350A1 (fr) | 1996-11-21 |
| WO1996036350B1 true WO1996036350B1 (fr) | 1997-01-03 |
Family
ID=23768427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/006779 WO1996036350A1 (fr) | 1995-05-19 | 1996-05-13 | Utilisation d'il-13 pour induire la 15-lipoxygenase |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5830453A (fr) |
| EP (1) | EP0831889A4 (fr) |
| JP (2) | JPH11505247A (fr) |
| AU (1) | AU6022496A (fr) |
| CA (1) | CA2221449A1 (fr) |
| WO (1) | WO1996036350A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6509313B1 (en) * | 1996-02-28 | 2003-01-21 | Cornell Research Foundation, Inc. | Stimulation of immune response with low doses of cytokines |
| US6242473B1 (en) * | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| WO2001077332A2 (fr) * | 2000-04-07 | 2001-10-18 | Heska Corporation | Compositions et methodes en rapport avec des recepteurs canins d'immunoglobuline g (igg) et d'il-13 |
| JP4676054B2 (ja) * | 2000-10-16 | 2011-04-27 | 友昭 星野 | 肥満および肥満関連疾病治療薬並びにその評価方法 |
| WO2003007685A2 (fr) | 2001-07-17 | 2003-01-30 | University Of Florida | Detection et traitement de troubles de l'appareil genital |
| WO2003105824A1 (fr) * | 2002-06-14 | 2003-12-24 | Alcon, Inc. | Utilisation topique de composes d'acide hydroxyeicosatetraenoique pour le traitement du psoriasis |
| US7666411B2 (en) * | 2002-06-14 | 2010-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of treating and preventing colitis involving IL-13 and NK-T cells |
| US8338180B2 (en) | 2003-06-10 | 2012-12-25 | The J. David Gladstone Institutes | Methods for treating lentivirus infections |
| ATE492563T1 (de) * | 2004-11-17 | 2011-01-15 | Amgen Inc | Vollständige humane monoklonale antikörper gegen il-13 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5079261A (en) * | 1989-04-28 | 1992-01-07 | Brigham And Women's Hospital | Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis |
| CA2142860A1 (fr) * | 1992-08-21 | 1994-03-03 | Gregorio Aversa | Interleukine humaine 13 |
-
1995
- 1995-05-19 US US08/445,311 patent/US5830453A/en not_active Expired - Fee Related
-
1996
- 1996-05-13 JP JP8534942A patent/JPH11505247A/ja not_active Ceased
- 1996-05-13 CA CA002221449A patent/CA2221449A1/fr not_active Abandoned
- 1996-05-13 WO PCT/US1996/006779 patent/WO1996036350A1/fr not_active Application Discontinuation
- 1996-05-13 EP EP96917810A patent/EP0831889A4/fr not_active Withdrawn
- 1996-05-13 AU AU60224/96A patent/AU6022496A/en not_active Abandoned
-
2005
- 2005-02-01 JP JP2005025745A patent/JP2005120111A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bittiner et al. | A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis | |
| Loria et al. | Regulation of the immune response by dehydroepiandrosterone and its metabolites | |
| US5874444A (en) | Poly (ADP-ribose) polymerase inhibitors to treat diseases associated with cellular senescence | |
| EP1310249B1 (fr) | Utilisation d'acides gras polyinsaturés pour la prévention primaire d'accidents cardio-vasculaires | |
| US5525618A (en) | Method of treating bone disease with pyridine, carboxamide and carboxylic derivatives | |
| Pai et al. | Potential of ozonated sesame oil to augment wound healing in rats | |
| US4870101A (en) | Method of inhibiting interleukin-1 release | |
| WO1994023722A1 (fr) | Activite de tamponnage de l'hydrocortisone | |
| MXPA01007662A (es) | Epa de etilo altamente purificado y otros derivados de epa para desordenes psiquiatricos y neurologicos. | |
| NO934768L (no) | Sammensetning av L-DOPA-estere | |
| AU2347500A (en) | Use of long-chain n-alkyl derivatives of deoxynojirimycin for the manufacture ofa medicament for the treatment of glycolipid storage diseases | |
| JPH04300873A (ja) | 睡眠障害治療剤 | |
| JPH0640904A (ja) | 医薬組成物 | |
| RO108220B1 (ro) | Preparate farmaceutice,pentru combaterea carceilor musculari si procedeu de obtinere a acestora | |
| WO1996036350B1 (fr) | Utilisation d'il-13 pour induire la 15-lipoxygenase | |
| TWI280880B (en) | Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances | |
| RU2161482C2 (ru) | Применение терпеновых соединений для уменьшенного выделения арахидоновой кислоты и медиаторов воспаления | |
| US5478566A (en) | Stimulation of cytokine production | |
| Takahashi et al. | Inhibition of tumor necrosis factor prevents warming-induced sleep responses in rabbits | |
| AU601554B2 (en) | Method of inhibiting interleukin-1 release | |
| Banner et al. | Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors | |
| Chander et al. | Lipid peroxidation of hyperlipemic rat serum lipoproteins in chronic ethanol and acetaldehyde administration | |
| EP0676203A1 (fr) | Composition pharmaceutiques des composés ayant une activité anti-glucocorticoide pour la prévention ou traitement des manifestations liées au syndrome de sevrage spontané ou précipité des narcotiques | |
| US5854271A (en) | Effective method for the amelioration and prevention of tissue and cellular damage | |
| US4459310A (en) | Method for cholesterol lowering |